This is interesting, as most data looking at ERBB2/HER2 status and clinical outcomes have shown that HER2 positivity is associated with high tumor grade, lymph node metastasis, and UC-specific mortality [9,28]. This evidence concerns the gene ERBB2 and metastatic malignant neoplasm in the lymph nodes.